Cargando…
Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study
Statins, commonly used to treat hypercholesterolemia, have also been proposed as anti-cancer agents. The identification of a predictive marker is essential. The 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (HMGCR), which is inhibited by statins, might serve as such a marker. Thorough antibody val...
Autores principales: | Bjarnadottir, Olöf, Feldt, Maria, Inasu, Maria, Bendahl, Pär-Ola, Elebro, Karin, Kimbung, Siker, Borgquist, Signe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969108/ https://www.ncbi.nlm.nih.gov/pubmed/31953433 http://dx.doi.org/10.1038/s41598-019-57323-9 |
Ejemplares similares
-
Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study
por: Inasu, Maria, et al.
Publicado: (2022) -
Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial
por: Feldt, Maria, et al.
Publicado: (2015) -
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
por: Inasu, Maria, et al.
Publicado: (2021) -
High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer
por: Kimbung, Siker, et al.
Publicado: (2016) -
Insensitivity to atorvastatin is associated with increased accumulation of intracellular lipid droplets and fatty acid metabolism in breast cancer cells
por: Lettiero, Barbara, et al.
Publicado: (2018)